Assessment of severity of ICD (impulse control disorders)

BEHAVIORAL2 trials

Sponsors

University Hospital, Strasbourg, France

Conditions

Parkinson Disease

Phase 2

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

CompletedNCT03947216

University Hospital, Strasbourg, FranceParkinson Disease

Start: 2020-10-23End: 2024-06-17Updated: 2026-03-16

Unknown Phase

Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Not yet recruitingNCT06754553

University Hospital, Strasbourg, FranceParkinson Disease

Start: 2025-02-28End: 2026-02-28Target: 100Updated: 2025-01-01